A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

The orchestration of T cell activation is central to immune defence and self-tolerance. Recent advances have revealed that T cells integrate signals from their antigen receptors alongside a network of ...

Immunotherapy has revolutionized the way physicians treat patients. Previously, chemotherapy was the standard-of-care with the goal to eliminate tumor cells by dysregulating their ability to ...

Researchers have developed a new class of antibodies that amplify the immune system’s ability to fight cancer. By clustering ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Cell isolation and activation are critical for cell therapy development and manufacturing. Ease of use, regulatory compliant and financial sustainability are among the most important considerations.

The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...